Colorectal cancer is the 3rd most common and 2nd most deadly cancer in the world. Ginger is one of the most studied dietary compounds in colorectal chemoprevention, with promising clinical results.
The reference clinical trial
A randomized clinical trial (Cancer Prevention Research, 2013) in patients at high risk of colorectal cancer shows that 2 g of ginger/day for 28 days:
- Reduces colonic cell proliferation (a marker of tumor risk)
- Increases apoptosis (programmed cell death) of precancerous cells
- Reduces colorectal PGE2 levels by 28% (pro-tumor prostaglandin)
Anticancer mechanisms
- Selective apoptosis: 6-gingerol and 6-shogaol induce the death of colorectal cancer cells while sparing healthy cells
- Anti-angiogenesis: blocks the formation of new vessels that feed tumors
- Inhibition of NF-κB: a major transcription factor in colorectal carcinogenesis
- Modulation of the microbiome-prebiotic-digestive-science-2026">microbiome: promotes butyrate-producing bacteria, which protect the colon
Polyps and prevention
Adenomatous polyps precede 95% of colorectal cancers. Ginger reduces proliferation markers in the colonic mucosa, suggesting an effect on the formation and growth of polyps. In combination with turmeric-poivre-noir-synergie-bienfaits">turmeric (present in INTI), the chemopreventive effect is synergistic.
Sugar and colorectal cancer
Sugar and insulin resistance are recognized risk factors for colorectal cancer. INTI, with 1.19 g/100 ml, offers the chemopreventive benefits of ginger without the glycemic risk.
Preventive protocol
- General population (>50 years old): 1-2 INTI shots/day
- History of polyps/familial colorectal cancer: 2-3 INTI shots/day
- This protocol does not replace screening (colonoscopy) or oncological follow-up
Conclusion
Ginger is a colorectal chemopreventive validated by clinical trials. INTI Drink — ginger + turmeric, sugar-free — is a judicious dietary supplement for colon health.